Glaxosmithkline Pharmaceuticals Ltd vs Kwality Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2479 as of 07 May 15:11 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Kwality Pharmaceuticals Ltd changed from 3.8 on March 2021 to 22.6 on March 2025 . This represents a CAGR of 42.84% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Kwality Pharmaceuticals Ltd changed from ₹ 58.11 crore on March 2021 to ₹ 901.74 crore on March 2025 . This represents a CAGR of 73.05% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Kwality Pharmaceuticals Ltd for the Dec '25 is ₹ 123.97 crore as compare to the Sep '25 revenue of ₹ 111.95 crore. This represent the growth of 10.74% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Kwality Pharmaceuticals Ltd for the Dec '25 is ₹ 29.65 crore as compare to the Sep '25 ebitda of ₹ 26.25 crore. This represent the growth of 12.95% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Kwality Pharmaceuticals Ltd changed from ₹ 8.35 crore to ₹ 16 crore over 7 quarters. This represents a CAGR of 45.01% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Kwality Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Limited was Incorporated on May 4th 1983 when its founder Mr. Ramesh Arora was inspired to begin his own venture leaving behind the already flourishing family business of spinning and aromatics.
With little background of finished pharmaceuticals and high held spirits and will, he started this business.
He received his first drug license in 1981 approved for liquid oral manufacturing.
Presently, the Company has 56 different sections available at their production centres. Kwality Pharmaceuticals Ltd. are manufacturer of finished pharmaceutical formulations in a Liquid Orals, Dry Syrups, Tablets, Capsules, Sterile Powder for Injections and small volume injectables.
The Company has the most modern & sophisticated Plant, Equipment, technique, and workforce.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Kwality Pharmaceuticals Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Kwality Pharmaceuticals Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,069 Cr while Market cap of Kwality Pharmaceuticals Ltd is 1,790 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Kwality Pharmaceuticals Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Kwality Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Kwality Pharmaceuticals Ltd?

As of May 7, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2424.3. On the other hand, Kwality Pharmaceuticals Ltd stock price is INR ₹1725.95.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Kwality Pharmaceuticals Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Kwality Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.